12 Liver Cancer 1 1 0 8 8 45 http://clinicaltrials.dfhcc.harvard.edu/trials/45 AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer Phase 2 165 http://clinicaltrials.dfhcc.harvard.edu/trials/165 Sorafenib Thearpy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer The purpose of this research study is to determine the effectiveness of sorafenib prior to a procedure called radiofrequency ablation for the treatment of hepatocellular cancer. Radiofrequency ablation (RF ablation) involves inserting a needle into tumor tissue and administering heat to the tumor tissue that is sufficient to kill the tumor cells. The needle, called an electrode, is attached to an energy device (generator) that produces heat. After the needle is placed in the tumor tissue, it is heated to a temperature that will kill the tumor cells. Radiofrequency ablation has been used to treat many types of tumors. Sorafenib has been approved by the FDA for metastatic kidney cancer and hepatocellular cancer that cannot be treated with surgery. The use of sorafenib prior to RF ablation in this study is "investigational" and has not been approved by the FDA. "Investigational" means that this combination is still being studied and that research doctors are trying to find out more about it. In this study, the study doctors hope to test the following: Understand the extent to which the combination of sorafenib and RFA may be done practically and successfully. Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer Phase 2 1347 http://clinicaltrials.dfhcc.harvard.edu/trials/1347 Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma In this study the investigators will be studying the effects of proton beam radiation therapy. This is a very accurate kind of treatment that has been shown to affect less normal tissue than a photon radiation beam. The accuracy allows the investigators to more safely increase the amount of radiation delivered to eliminate cancer. This accuracy will potentially reduce side effects that participants would normally experience using photon radiation therapy. The purpose of this study is to determine if radiation using proton beam therapy will kill the cancer cells in the participants liver. Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer Phase 2 326 http://clinicaltrials.dfhcc.harvard.edu/trials/326 RAD001 in Advanced Hepatocellular Carcinoma Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safely (without causing severe side effects) and to learn the effects (good or bad) RAD001 has on participants with liver cancer. Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer Phase 1/Phase 2 355 http://clinicaltrials.dfhcc.harvard.edu/trials/355 A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer. Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer Phase 1 228 http://clinicaltrials.dfhcc.harvard.edu/trials/228 Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement. Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer 38 Solid Tumor/Phase I http://clinicaltrials.dfhcc.harvard.edu/diagnoses/38-solid-tumor-phase-i Phase 1 96 http://clinicaltrials.dfhcc.harvard.edu/trials/96 Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue. Recruiting 19 Pancreatic Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/19-pancreatic-cancer 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer N/A 1229 http://clinicaltrials.dfhcc.harvard.edu/trials/1229 Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation). Recruiting 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer